Abstract：Objective: To analyze the influencing factors of fatty liver in type 2 diabetic patients with Postmenopausal. Methods: From October 2012 to October 2014, the general condition, lifestyle and self-management data of hospitalized patients were collected. 136 cases of postmenopausal type 2 diabetes mellitus with fatty liver were selected as observation group, and 138 cases of postmenopausal patients with type 2 diabetes mellitus as control group. The differences of the data between the two groups were compared. Results: There was significant difference between the two groups of high fat diet, high sugar diet, physical exercise and self management index (P < 0.05). Multivariate logistic regression analysis showed that high fat diet (OR = 2.324, 95%CI = 1.409 to 3.833) and high carbohydrate diet (OR = 1.866, 95%CI = 1.118 to 3.114) were risk factors for fatty liver. Conclusions: The influencing factors of fatty liver in postmenopausal patients with type 2 diabetes are diet habits, physical exercise and self-management. High glucose and high-fat diet are risk factors for fatty liver.
葛晓春, 王英南, 高宇, 刘晓燕, 王旭泽. 绝经后女性2型糖尿病患者合并脂肪肝的影响因素研究[J]. 河北医学, 2018, 24(2): 293-296.
GE XiaoChun, WANG YingNan, GAO Yu, et al. Study on the Factors of Influencing Fatty Liver in PostmenopausalWomen Complicated with Type 2 Diabetes. HeBei Med, 2018, 24(2): 293-296.
[1] 高鑫.非酒精性脂肪性肝病与代谢紊乱研究进展[J].中华内分分泌学分会《肝病与代谢》学组年会暨2012年复旦大学,脂肪肝与代谢紊乱论坛论文集,2012. [2] Angulo P1, Lindor KD. Non-alcoholic fatty liver disease[J].Gastroenterol Hepatol,2002,17(1):86~90. [3] Torres D M, Williams C D, Harrison S A. Features, diagnosis and treatment of nonalcoholic fatty liver disease[J].Clin Gastroenterol Hepatol, 2012,10(8): 837~858. [4] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中国医学前沿杂志(电子版),2011,3(6):54. [5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.中国非酒精性脂肪性肝病诊疗指南(2010修订版)[J].中国医学前沿杂志(电子版),2012,4(7):4~10. [6] 范建高,曾民得.脂肪性肝病[M].北京:人民卫生出版社,2005.54. [7] Polotsky H N, Polotsky A J. Metabolic implications of menopause[J].Semin Reprod Med, 2010, 28(5): 426~434. [8] GaedeP, PedersenO.Target intervention against multiple-risk markers to reduce cardiovascular disease in patients with type 2 diabetes[J].Ann Med. 2004;36(5): 355~366.
2018, Vol. 24 
冀公网安备13080202000677号